AngioDynamics Loses US$42m Market Value But Insiders See Windfall Of US$58k

Insiders who bought AngioDynamics, Inc. (NASDAQ:ANGO) stock lover the last 12 months are probably not as affected by last week’s 11% loss. After taking the recent loss into consideration, the US$135.8k worth of stock they bought is now worth US$194.1k, indicating that their investment yielded a positive return.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

AngioDynamics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by CEO, President & Director James Clemmer for US$121k worth of shares, at about US$6.03 per share. We do like to see buying, but this purchase was made at well below the current price of US$8.60. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

In the last twelve months insiders purchased 22.57k shares for US$136k. But they sold 4.06k shares for US$50k. In total, AngioDynamics insiders bought more than they sold over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for AngioDynamics

AngioDynamics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Does AngioDynamics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that AngioDynamics insiders own 6.4% of the company, worth about US$23m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The AngioDynamics Insider Transactions Indicate?

It doesn't really mean much that no insider has traded AngioDynamics shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Overall we don't see anything to make us think AngioDynamics insiders are doubting the company, and they do own shares. Of course, the future is what matters most. So if you are interested in AngioDynamics, you should check out this free report on analyst forecasts for the company.

Of course AngioDynamics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.